patent for semaglutide The upcoming expiry of the in India in mid-March 2026 is expected to transform the country's diabetes treatment landscape. Ahead of this, industry experts predict that the development will open A Snapshot of the Semaglutide

This timing positions Canada ahead of the United States and European markets, where patent protections remain in effect for additional years

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that works by increasing insulin secretion and suppressing glucagon secretion, leading to lower blood sugar levels

Emerging Research in Se Nanoparticles and Precision Medicine Recent advances in nanotechnology have introduced Se nanoparticles (SeNPs) as a promising form of Se supplementation, particularly within the context of precision medicine [106]

Brief interventions to reduce risky drinking and drug use have been well validated in a variety of populations and offer the potential to improve diabetes medication taking and outcome [141]

GLP1s a class of medicines originally developed for diabetes but now widely used for weight loss have become some of the fastestgrowing pharmaceutical products in the country